HAVCR2 and breast cancer: These approaches are being tested in several clinical trials for solid tumors, such as MBG453 (NCT02608268), TSR-022 (NCT02817633), and LY3321367 (NCT03099109) [139–141], highlighting the importance of TIM-3 in BC therapy.